Shinichiro Yamada
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 27
- Liver physiology and pathology 14
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 11
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 15
- Geriatrics and Gerontology top 5%
- Surgery top 5%
- Cholangiocarcinoma and Gallbladder Cancer Studies 22
- Pancreatic function and diabetes 12
-
- Liver Disease Diagnosis and Treatment 14
-
- Mesenchymal stem cell research 9
- Co-authors
- Tetsuya IkemotoMitsuo ShimadaYuji MorineYu SaitoSatoru ImuraShuichi IwahashiTohru UtsunomiyaYusuke Arakawa
- Cited by
- HepatologyCancer ResearchOncology
- Partner nations
- JapanUnited StatesGermany
In The Last Decade
Shinichiro Yamada
134 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 125
- Hepatology 524
- Cancer Research 401
- Oncology 605
- Geriatrics and Gerontology 76
- Surgery 649
Countries citing papers authored by Shinichiro Yamada
This map shows the geographic impact of Shinichiro Yamada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinichiro Yamada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinichiro Yamada more than expected).
Fields of papers citing papers by Shinichiro Yamada
This network shows the impact of papers produced by Shinichiro Yamada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinichiro Yamada. The network helps show where Shinichiro Yamada may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shinichiro Yamada, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 9 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 27 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 1 | |
| 8 | 2022 | 3 | |
| 9 | 2022 | 0 | |
| 10 | 2021 | 9 | |
| 11 | 2021 | 10 | |
| 12 | 2021 | 21 | |
| 13 | 2021 | 33 | |
| 14 | 2020 | 2 | |
| 15 | 2020 | 21 | |
| 16 | 2020 | 9 | |
| 17 | 2019 | 21 | |
| 18 | 2019 | 10 | |
| 19 | Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma. | 2016 | 18 |
| 20 | 2009 | 2 |
About Shinichiro Yamada
Shinichiro Yamada is a scholar working on Hepatology, Cancer Research and Oncology, having authored 147 papers that have together received 2.1k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (27 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (22 papers), Pancreatic and Hepatic Oncology Research (15 papers), Liver physiology and pathology (14 papers), Liver Disease Diagnosis and Treatment (14 papers), Pancreatic function and diabetes (12 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Mesenchymal stem cell research (9 papers). The work is most often cited by research in Hepatology (524 citations), Cancer Research (401 citations) and Oncology (605 citations). Shinichiro Yamada has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saito, Satoru Imura, Shuichi Iwahashi, Tohru Utsunomiya, Yusuke Arakawa, Chie Takasu and Katsuki Miyazaki.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.